Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.

[1]  F. Ponchel,et al.  IL-7 and lymphopenia. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[2]  E. Brown,et al.  Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing Receptor , 2010, Molecular Pharmacology.

[3]  A. Silman,et al.  Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  R. Owens,et al.  Structural and Functional Insights of RANKL–RANK Interaction and Signaling , 2010, The Journal of Immunology.

[5]  E. Mathiesen,et al.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-κB ligand: the Tromsø Study , 2010, Osteoporosis International.

[6]  J. Compston,et al.  Osteoporosis: social and economic impact. , 2010, Radiologic clinics of North America.

[7]  E. Lewiecki.  Denosumab – an emerging treatment for postmenopausal osteoporosis , 2010, Expert opinion on biological therapy.

[8]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[9]  E. Lewiecki.  Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. , 2009, Journal of women's health.

[10]  P. Kostenuik,et al.  Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. , 2009, Bone.

[11]  L. Hofbauer,et al.  Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. , 2009, Bone.

[12]  B. Larijani,et al.  Relationships among serum receptor of nuclear factor-&kgr;B ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineraldensity in postmenopausal women: osteoimmunity versus osteoinflammatory , 2009, Menopause.

[13]  M. Rybchyn,et al.  Osteoblasts play key roles in the mechanisms of action of strontium ranelate , 2009, British journal of pharmacology.

[14]  P. Geusens.  Emerging treatments for postmenopausal osteoporosis – focus on denosumab , 2009, Clinical interventions in aging.

[15]  P. Halbout,et al.  Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response , 2009, Osteoporosis International.

[16]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  T. Onouchi,et al.  Implications of Measuring Soluble Receptor Activators of Nuclear Factor-κB Ligand and Osteoprotegerin in Bone Metabolism of Elderly Women , 2009, Gerontology.

[18]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  D. Felsenberg,et al.  Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[20]  J. S. San Martin,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  K. Arisawa,et al.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in post-menopausal women , 2008, Journal of endocrinological investigation.

[22]  G. Ning,et al.  Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women , 2008, Osteoporosis International.

[23]  N. Fazzalari,et al.  Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males , 2008, Arthritis research & therapy.

[24]  P. Miller,et al.  Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  C. Rosen,et al.  Aging Impairs IGF‐I Receptor Activation and Induces Skeletal Resistance to IGF‐I , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  E. Barrett-Connor,et al.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. , 2007, European journal of endocrinology.

[27]  J. Penninger,et al.  Osteoprotegerin Reduces the Serum Level of Receptor Activator of NF-κB Ligand Derived from Osteoblasts1 , 2007, The Journal of Immunology.

[28]  S. Khalifé,et al.  Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population , 2006, Clinical endocrinology.

[29]  G. Paolisso,et al.  Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. , 2006, European journal of endocrinology.

[30]  Ling Wang,et al.  Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL. , 2006, Cellular & molecular immunology.

[31]  P. Härkönen,et al.  Estrogen and Testosterone Use Different Cellular Pathways to Inhibit Osteoclastogenesis and Bone Resorption , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  Steven W. Martin,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Eastell,et al.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  U. Iwaniec,et al.  Aging Increases Stromal/Osteoblastic Cell‐Induced Osteoclastogenesis and Alters the Osteoclast Precursor Pool in the Mouse , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  G. Sigurdsson,et al.  Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover , 2005, Osteoporosis International.

[36]  Hyun Ah Choi,et al.  The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone , 2005, Clinical endocrinology.

[37]  M. Muñoz-Torres,et al.  The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women , 2005, Osteoporosis International.

[38]  Sun Woo Kim,et al.  Circulating osteoprotegerin and receptor activator of NF‐κB ligand system are associated with bone metabolism in middle‐aged males , 2005, Clinical endocrinology.

[39]  K. Chihara,et al.  Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[40]  P. Pietschmann,et al.  Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.

[41]  C. Bonelli,et al.  Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status , 2003, Wiener Klinische Wochenschrift.

[42]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[43]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[44]  B. Halloran,et al.  Expression of RANKL and OPG Correlates With Age‐Related Bone Loss in Male C57BL/6 Mice , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  J. Compston,et al.  The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. , 2003, Bone.

[46]  R. Eastell,et al.  Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. , 2002, The Journal of clinical endocrinology and metabolism.

[47]  S. Khosla,et al.  Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. , 2002, European journal of endocrinology.

[48]  L. Melton,et al.  Correlates of Osteoprotegerin Levels in Women and Men , 2002, Osteoporosis International.

[49]  D O Slosman,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[50]  K. Preissner,et al.  RANK Ligand and Osteoprotegerin Paracrine Regulators of Bone Metabolism and Vascular Function , 2002 .

[51]  W. O'Fallon,et al.  Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. , 2002, The Journal of clinical endocrinology and metabolism.

[52]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[53]  R. Ziegler,et al.  Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. , 2001, European journal of endocrinology.

[54]  P. Delmas,et al.  Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. , 2001, The Journal of clinical endocrinology and metabolism.

[55]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[56]  J. Lorenzo,et al.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999 .

[57]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[58]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[59]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[60]  Sakae Tanaka,et al.  PEDF regulates osteoclasts via osteoprotegerin and RANKL. , 2010, Biochemical and biophysical research communications.

[61]  Y. Yazici,et al.  Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.

[62]  T. Niu,et al.  Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men , 2005, Human Genetics.

[63]  Won-Young Lee,et al.  Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. , 2005, Metabolism: clinical and experimental.

[64]  L. Sun,et al.  Relationships Between the Changes of Serum Levels of OPG and RANKL with Age, Menopause, Bone Biochemical Markers and Bone Mineral Density in Chinese Women Aged 20-75 , 2004, Calcified Tissue International.

[65]  E. Mariani,et al.  Soluble Receptor Activator of Nuclear Factor-κB Ligand (sRANKL)/Osteoprotegerin Balance in Ageing and Age-Associated Diseases , 2004, Biogerontology.

[66]  M. Fenger,et al.  Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios , 2003, Journal of Bone and Mineral Metabolism.

[67]  R. L. Cain,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Catabolic Effects of Continuous Human PTH (1–38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation , 2022 .